Filter posts

“Diverse Candidates Can Win If They Can Get the Interview.”

Diversity is gaining more attention among biotech investors and companies alike. At entry level, 50% …

#BIF17: Looking Ahead to 2018 Policy Landscape

The past year has seen a number of important changes in the legislative and policy …

A Discussion on Value at #BIF17

In a recent op-ed, BIO President and CEO Jim Greenwood wrote about a promising trend …

“Invest in What’s Cool. Invest in Science that Matters.”

One reality of the biotech industry that’s often overlooked is that 90% of biotech companies …

BIO Investor Forum Opens Amid Positive Signs for Emerging Biotechs

Today the BIO Investor Forum opens in San Francisco amid optimism in the biotech sector. …

ONE HEALTH event discusses solutions and innovations in biotechnology in Brazil

Joseph Damond, Executive Vice President of International Affairs at BIO led a keynote discussion on …

Make History at BIO 2018

As we near the end of 2017, I’d like to take a moment to reflect …

Challenges and Opportunities in Personalized Medicine

Last week the sixth annual Patient and Health Advocacy Summit brought hundreds of patient advocates, …

Patient and Industry Collaboration: Key to Successful Clinical Trials?

During the BIO Patient & Health Advocacy Summit last week, a panel led by Julie …

FDA’s Dr. Theresa Mullin Addresses BIO Patient and Health Advocacy Summit

“So, Theresa, where did you grow up? Did you have any siblings?” asked Marc Boutin, …